Efficacy and Safety of Low-dose Ticagrelor

Summary

Guideline recommendations on the use of dual antiplatelet therapy have been formulated that ticagrelor 90 mg twice daily plus aspirin in preference to clopidogrel 75mg daily plus aspirin for ACS patients. Recent study found that ticagrelor 90mg twice a day orally could significantly reduce the occurrence of clopidogrel resistance and adverse cardiovascular events. The previous studies have reported that half-dose ticagrelor had the similar inhibitory effect on platelet aggregation as the standard-dose ticagrelor, which was significantly stronger than that in the clopidogrel group. One-quarter standard-dose ticagrelor provided greater degree of platelet inhibition than standard dose clopidogrel in Chinese patients with stable CAD. But large-scale clinical trials are still needed to confirm the effects of low-dose ticagrelor on platelet function in Chinese patients with coronary heart disease.

Conditions

• Coronary Artery Disease

Interventions

DRUG

Ticagrelor

ticagrelor 45 mg twice daily for 5 consecutive days at least.

DRUG

ticagrelor

ticagrelor 90 mg once daily for 5 consecutive days at least.

DRUG

ticagrelor

ticagrelor 90 mg twice daily for 5 consecutive days at least.

DRUG

clopidogrel

clopidogrel 75 mg once daily for 5 consecutive days at least.

Sponsors & Collaborators

• Beijing Anzhen Hospital

  collaborator OTHER

• The First Affiliated Hospital of Dalian Medical University

  collaborator OTHER

• The Central Hospital of Jia Mu Si City

  collaborator UNKNOWN

• First Affiliated Hospital of Kunming Medical University

  collaborator OTHER

• RenJi Hospital

  collaborator OTHER

• Tianjin Medical University General Hospital

  collaborator OTHER

• Weifang People's Hospital

  collaborator OTHER

• Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

  collaborator OTHER

• Shengjing Hospital

  collaborator OTHER

• Shaanxi Provincial People's Hospital

  collaborator OTHER

• First Affiliated Hospital of Harbin Medical University

  lead OTHER

Principal Investigators

• Yue Li, MD · Cardiovascular Department, the First Affiliated Hospital of Harbin Medical University

Study Design

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

SINGLE

Model

PARALLEL

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2017-12-13

Primary Completion

2018-12-13

Completion

2019-02-13

Countries

• China

Study Locations